Large Extracellular Loop of Tetraspanin as a Potential Vaccine Candidate for Filariasis

Gajalakshmi Dakshinamooorthy¹, Gnanasekar Munirathinam¹, Kristen Stoicescu¹, Maryada Venkatarami Reddy², Ramaswamy Kalyanasundaram¹*¹

¹ Department of Biomedical Sciences, University of Illinois College of Medicine at Rockford, Rockford, Illinois, United States of America, ² Department of Biochemistry, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India

Abstract

Lymphatic filariasis affects nearly 120 million people worldwide and mass preventive chemotherapy is currently used as a strategy to control this infection. This has substantially reduced the incidence of the infection in several parts of the world. However, a prophylactic vaccine would be more effective in preventing future infections and will supplement the mass chemotherapy efforts. Unfortunately, there is no licensed vaccine available currently to prevent this infection. Molecules expressed on the surface of the parasite are potential candidates for vaccine development as they are exposed to the host immune system. In this study we show that the large extracellular loop of tetraspanin (TSP LEL), a protein expressed on the cuticle of Brugia malayi and Wuchereria bancrofti is a potential vaccine candidate. Our results showed that BmTSP LEL is expressed on the surface of B. malayi infective third stage larvae (L3) and sera from human subjects who are putatively immune to lymphatic filariasis carry high titer of IgG1 and IgG3 antibodies against BmTSP LEL and WbTSP LEL. We also showed that these antibodies in the sera of human subjects can participate in the killing of B. malayi L3 in an antibody dependent cell-mediated cytotoxicity mechanism. Vaccination trials in mice showed that close to 64% protection were achieved against challenge infections with B. malayi L3. Immunized animals showed high titer of anti-WbTSP LEL IgG1, IgG2a and IgG2b antibodies in the sera and IFN-γ secreting cells in the spleen. Onchocerca volvulus another filarial parasite also expresses TSP LEL. Cross-reactivity studies showed that IgG1 antibody in the sera of endemic normal subjects, recognize OvTSP LEL. Similarly, anti-OvTSP LEL antibodies in the sera of subjects who are immune to O. volvulus were also shown to cross-react with rWbTSP LEL and rBmTSP LEL. These findings thus suggested that rTSP LEL can be developed as a potential vaccine candidate against multiple filarial infections.

Introduction

Lymphatic filariasis (LF) affects 120 million people in 72 countries and more than 1.2 billion people are at the risk of acquiring the infections [1]. The disease is transmitted by mosquitoes carrying any of three parasitic nematodes: Wuchereria bancrofti, Brugia malayi, and Brugia timori. In the tropical and sub tropical regions of the world filarial infections are a major public health and socio-economic problem [2,3]. Mass drug administration is currently used as an approach to control this infection in endemic areas [4]. However, an effective prophylactic vaccine against lymphatic filariasis coupled with effective vector control measures can supplement the mass drug administration approach and speed up the effort to eliminate this infection in the endemic regions. Several potential vaccine candidates have been identified and evaluated from different laboratories [5-9], yet there is no effective vaccine available against this disease. This may be largely due to the complex life cycle stages of the parasites and the varied immune responses developed by the host to each antigen.

Lymphatic filarial parasites are notorious for evading the host immune responses by molecular mimicry and active modulation of the host immune responses [10]. Tetraspanin (TSP) family of proteins is one among the parasite antigens that plays an important role in host immunomodulation. TSPs are membrane-spanning proteins containing four transmembrane domains, three short intracellular domains, and two extracellular loops, EC1 and EC2 [11]. TSPs are abundantly expressed on the surface or body wall of several
helminth parasites including *S. mansoni* [12], *S. japonicum* [13] and in the nematode *C. elegans* [14]. TSP is believed to play important roles in signal transduction, cell proliferation, adhesion, migration, fusion and host-parasite interactions [15]. Among the various TSPs reported, TSP-2 identified from *Schistosoma mansoni* (*SmTSP-2*) is shown to be involved in the formation of tegument [13] which is critically important for the parasite’s survival in the host [16]. Since TSPs are expressed on the surface, they are easy targets for immune attack by host antibodies and cells [17]. Especially, the extracellular loops of TSP are more amenable to the host immune system. Given its critical role in the formation of tegument and survival of the parasite in the host, TSP has been a target for developing vaccine against *S. mansoni* [18-20]. Especially, the large extracellular loop (LEL) of *SmTSP-2* was shown to be highly effective as a vaccine immunogen conferring high levels of protection in mice against challenge infections [12]. Previously we reported the presence of *SmTSP-2* homologue in *B. malayi* parasites [21]. Since TSP-LEL appears to be a good vaccine candidate, in the present study we cloned *tsp lel* from lymphatic filarial parasites (*W. bancrofti* and *B. malayi*). We then expressed the recombinant *B. malayi* TSP LEL (*rBmTSP LEL*) and *W. bancrofti* TSP LEL (*rWbTSP LEL*) proteins and evaluated its vaccine potential in human and in mice.

Developing a single global vaccine which is effective against multiple infections is an attractive strategy for endemic regions where mixed infections are common. Administering vaccines separately for diseases require an increased number of visits, labor, side effects, and costs not to mention the various regulatory approvals needed to develop separate new vaccines. Generation of broadly protective “universal” vaccines restricted to species or groups of closely related pathogens or even cross-family or -kingdom vaccines might be useful to overcome some of the barriers in vaccine development [22]. Very few studies have attempted to identify these cross-species protective antigens. Among the eight filarial species that parasitize humans, lymphatic filariasis caused by *W. bancrofti* and *B. malayi* and onchocerciasis caused by *Onchocerca volvulus* are more common and occur as co-infection in several endemic regions [23,24]. These three parasites are also the major targets for vaccine development by a number of laboratories [23,25-27]. In this report we show that homologue of TSP-2 is expressed in *O. volvulus* and show significant sequence similarity to *BmTSP-2* and *WbTSP-2*. Therefore, in this study we have also attempted to evaluate the cross-protection potential of rTSP LEL from LF parasites against onchocerciasis.

**Materials and Methods**

**Ethics Statement**

Use of human subjects in this study was approved by the Institutional Review Board (IRB) of the University of Illinois, College of Medicine at Rockford; the New York Blood Center’s IRB and by an NIH accredited Institutional Review Board of the Medical Research Council Kumba, Cameroon and the IRB committee of Mahatma Gandhi Institute of Medical Sciences, Sevagram, Maharashtra, India. Informed written consent in native language was obtained from all the subjects before collecting the samples. Humane use of animals was performed in this study according to the guidelines for the care and use of laboratory animals and with the rules formulated under the Animal Welfare Act by the U.S. Department of Agriculture. The protocol was approved by The IACUC Committee of the University of Illinois, College of Medicine at Rockford and performed at a facility accredited by AAALAC and USDA.

**Parasites**

*Bru gia malayi* infective third stage larvae (L3) were obtained from the NIAID/NIH Filaria Research Reagent Resource Center (FR3) at the University of Georgia, Athens, GA.

**Human sera Samples**

Blood samples were collected after taking informed consent from clinically diagnosed filarial patients and from healthy adult individuals residing in Sevagram and surrounding villages in Maharashtra State, which are non-coastal endemic areas for nocturnally periodic *W. bancrofti* infection. Samples were also collected from volunteers who live in areas that are non endemic for filariasis. Parasitological examination of all individuals was done by detection of microfilareia in night blood smears. The presence of mf was further confirmed by membrane (Millipore-5m filters) filtration of 1.0 ml of heparinized venous blood [28]. The presence of circulating antigen was detected using a *WbSXP* based enzyme-linked immunosorbent assay (ELISA) [29]. About 10 ml of blood samples (5 ml in heparinized tubes) were collected from the following clinical groups of subjects (a) Endemic normal (EN) subjects, these are individuals who are asymptomatic and non-microfilaraemic residing in Sevagram (b) Asymptotic microfilaraemic subjects (MF) were classified based on the presence of circulating mf in blood. (c) Chronic Pathology (CP) patients include those subjects who exhibit lymph edema and other chronic clinical symptoms of filariasis. These CP patients did not carry circulating mf and (d) Non-endemic normal (NEN) subjects are healthy individuals who live in a non-endemic country and have no circulating parasites or antibodies in their sera and show no evidence of any clinical lymphatic filarial disease. Sera were separated from these blood samples and were stored at - 80°C until use. PBMC proliferation was performed using freshly collected blood samples from EN, MF and CP individuals. Sera samples from onchocerciasis immune (PI) and onchocerciasis infected individuals (INF) were collected from residents of 5 villages around Kumba, Cameroon, a hyperendemic area after obtaining the informed consent by signing or thumb printing a consent form after reading it or after the content of the form was read and/or explained to them. These villages were Marumba I, Marumba II, Boa Bakundu, Bombanda, and Bombele. All participants were born or had resided for more than 10 years in the villages. The standard skin snip test for detection of microfilareia (mf) was performed on each subject and clinical symptoms of onchocerciasis were recorded. The averages of the mf counts of four skin snips taken from each individual were used in estimating the
individual skin mf densities. None of the subjects had received ivermectin treatment prior to the collection of blood. Serum samples of 20 putatively immune (PI) subjects of onchocerciasis were studied. These individuals had no signs or history of onchocerciasis and were parasitologically negative during at least a two-year follow-up survey employing the standard skin snip test and a polymerase chain reaction (PCR) assay. Age, sex matched infected individuals were used for comparison as described before [30,31].

Cloning of tsp from three filarial parasites

Transcripts encoding TSP LEL proteins were amplified from *W. bancrofti*, *B. malayi* and *O. volvulus* L3 cDNA libraries. Primers were designed from the genebank sequence (Accession number EF397425.1) of *B. malayi* tetraspanin LEL domain. The same set of primers were used to amplify tsp lel from the cDNA libraries of all the three parasites; Forward primer sequence with BamiHI restriction sites 5′-CGGGATCCCGGGAAGGATCATAATTAAA-3′ and Reverse primer sequence with EcoR I 5′-CGGAATTCGGAATTTTGAGATGAAT-3′. PCR was performed with denaturation at 95°C, annealing at 50°C, and extension at 75°C. Five different PCR clones from each parasite species were sent out for sequencing at the DNA sequencing facility at UIC, Chicago. The results showed no difference in the sequences between the PCR clones. A multiple sequence alignment of helminth TSP LEL was then performed using ClustalW.

Expression and purification of rTSP LEL domain

*tsp lel* amplified from L3 cDNA libraries (*W. bancrofti*, *B. malayi* and *O. volvulus*) were cloned into pRSETA expression vector and transformed into BL21(DE3) pLysS *E. coli* expression host. *E. coli* cultures with pRSETA tsp plasmid was inoculated in 500ml of LB broth and incubated for 3 hours until the log phase of bacterial growth was reached (absorbance OD 0.6 at 600nm). 1 mM of isopropyl-beta-D-thiogalactopyranoside (IPTG) was added to the culture to induce the proteins expressions and incubated for an additional 3 hours. Recombinant *Wb*TSP LEL, *Bm*TSP LEL and *Ov*TSP LEL expressed as His-tag proteins were purified using IMAC column. SDS PAGE was run to check the purity of the recombinant proteins. Immunoblot was performed by probing with anti per-tetraspanin antibodies (Qiagen, Valencia, CA). Endotoxin was removed from the recombinant proteins using High Capacity Endotoxin removal resin (Thermo Fisher Scientific, Rockford, IL). Levels of endotoxin in the final recombinant protein preparation were confirmed by LAL assay (Gen Script, Piscataway, NJ) and were found to be below 4 EU/ml.

Immunization of mice

Six weeks old male Balb/c mice purchased from Charles River laboratory (Wilmington, MA) were divided into three groups with five mice in each group. Mice were immunized four times subcutaneously (s.c) with 15μg of recombinant tetrascapan proteins (*Wb*TSP LEL or *Bm*TSP LEL) in 100μl volume combined with 50μl of Imject alum (Thermo Fisher Scientific) given at 2 weeks interval. Control group of animals received only alum. Blood was collected from the retro-orbital space of each mouse two weeks after the final dose of immunization. This experiment was repeated twice times.

Immunofluorescence assay to evaluate the presence of TSP LEL on the surface of *B. malayi* L3

Presence of TSP LEL on the surface of infective larvae of *B. malayi* was analyzed by an immunofluorescence whole mount assay [32]. About 5-10 L3 were incubated with 1% BSA, 0.1% Triton X-100 in phosphate buffer saline (PBS) for two hours at 4°C under agitation in the microcentrifuge tube. Pooled mouse anti-BmTSP LEL sera (optimum dilution was found to be 1:25) diluted in 100μl volumes of blocking buffer was added to L3 and incubated at room temperature for 2 h. After washing with PBS, the parasites were incubated at RT for 1 h with anti-mouse IgG conjugated with fluorescein isothiocyanate (FITC, purchased from Thermo Fisher Scientific) at 1:1000 dilutions. After washing with PBS, the parasites were placed on to a glass slide and mounted with fluorophore mounting medium. After placing a cover slip, the edges were sealed and observed under a fluorescence microscope (Olympus, Center valley, PA) using 10X and 60X objective lens. Sera from mice immunized with alum or anti-mouse IgG FITC alone were used as negative controls (data not shown).

Analysis of total anti-TSP LEL IgG antibodies in the sera samples

IgG antibodies against *Wb*TSP LEL, *Bm*TSP LEL or *Ov*TSP LEL were evaluated in the sera of different filarial groups of subjects by indirect ELISA [33]. Briefly, wells of a 96 well microtiter ELISA plates were coated with 100 ng/well of recombinant proteins (*Wb*TSP LEL, *Bm*TSP LEL or *Ov*TSP LEL) in 0.05M carbonate-bicarbonate buffer, pH 9.6. After blocking the wells with 3% BSA in PBS-Tween 20 (PBS-T, 0.05%), 100μl of sera samples (1:100 diluted in PBS-T) from different groups of subjects with filarial infections (MF, CP, EN and NEN) were added to each well. Horse radish peroxidase-labeled Goat anti-human IgG was used as the secondary antibody. The color was developed using OPD substrate and absorbance was read at 450 nm in the ELISA reader (BioRad, Hercules, CA). Antigen-specific isotype of IgG antibodies present in the sera of different filarial groups were evaluated by indirect ELISA [34]. Biotinylated anti-human IgG1 (1:1000), IgG2 (1:15000), IgG3 (1:1000) and IgG4 (1:15000) isotypes (Sigma Aldrich, St. Louis, MO) were used as the secondary antibodies. Levels of anti-TSP LEL IgG and IgG isotype antibodies (Biolegend, San Diego, CA) were similarly measured in the sera of mice immunized with rTSP LEL proteins.

Levels of cross-reactive IgG1 and IgG3 antibodies against *Wb*TSP LEL was measured in the sera of *O. volvulus* putatively immune (PI) or *O. volvulus* infected individuals (INF) using an indirect ELISA described by MacDonald et al., [31]. Briefly, wells of a microtiter Immunoson 2 plates (Dynex, Chantilly, VA), were coated with 1 μg/ml *Wb*TSP LEL diluted in 0.05M carbonate-bicarbonate buffer, (pH 9.6) overnight at 4°C. Non-specific sites were blocked with 3% BSA in PBS-T for 2 h at
37°C. After washing the plates six times with PBS-T, individual serum samples that were pre-cleaned with E. coli lysate (400 μg/ml, Promega, Madison, WI) and diluted to 1:100 in binding buffer (1% non-fat milk in PBS-T) were added to each well in duplicate and incubated for 1 h at 37°C. Pre-clarification using E. coli lysate was performed as described previously [30] to remove any cross-reacting E. coli specific antibodies in the sera samples that may interfere in our assay since all our recombinant proteins were prepared in E. coli. Monoclonal antibodies (1:1000 dilution) against different human IgG subclasses (Hybridoma Reagent Laboratory, Kingsville, MD) was used as the secondary antibodies and horseradish peroxidase-conjugated goat anti-mouse IgG (H+L) (KPL, Gaithersburg, MD, 1:8000, incubated for 60 min at room temperature) was used as the detection antibodies. Absorbance (OD450) was read after stopping the reaction with an equal volume of 1M H2SO4 using an E_{max} ELISA reader (Molecular Devices, Sunnyvale, CA).

We also depleted anti-WbTSP LEL IgG antibodies from the sera of EN subjects by passing the sera through a cobalt IMAC resin column coupled to rWbTSP LEL [35]. Briefly, 1 mg of his-tagged rWbTSP LEL was coupled to 2 ml bed volume of IMAC resin for 2 hrs at 4°C. After washing the resin once with 10 ml of PBS (pH.8), 200 ml of pooled sera was added and incubated overnight at 4°C. After incubation, the resin mixture was centrifuged for 2 min at 750 rpm and the supernatant were collected. Total IgG was removed by incubating sera samples with Protein A gel beads (Thermo Fisher Scientific). Depletion of rWbTSP LEL specific antibodies in the sera samples was confirmed by an indirect ELISA as described above.

Antibody dependent cell mediated cytotoxicity (ADCC) assay using human and mouse sera

In vitro ADCC assay was performed using both human and mice sera as described previously [34]. Briefly, ten L3 of B. malayi were incubated with 2 x 10^5 peripheral blood mononuclear cells (PBMC) collected from normal healthy subjects, 50 μl of pooled EN sera samples and 50 μl of RPMI 1640 media in a 96 well culture plate (Thermo Fisher Scientific). After 48 h of incubation at 37°C and 5% CO2, the larval viability was determined under a light microscope (400X). Viable larvae were actively moving, coiled and translucent. Dead larvae were flaccid, transparent, damaged and had clumps of cells attached to them. ADCC was estimated as percent larval death calculated using the following formula: Number of dead larvae + Total number of larvae x 100. ADCC assay was also performed using sera samples from rTSP LEL immunized mice. 2 x 10^5 peritoneal exudates cells (PEC) from normal mice were used as effector cells in these assays.

Analysis of cross reactivity between lymphatic filarial TSP LEUs and Onchocerca TSP LEL

Cross reactivity of anti-WbTSP LEL IgG antibodies against OvTSP LEL was evaluated using an indirect ELISA as described above. The cross reactivity was also evaluated between BmTSP LEL, WbTSP LEL and OvTSP LEL using an immunoblot analysis. Briefly, nitrocellulose membrane blotted with the each of the recombinant proteins was probed with sera collected from mice immunized with rBmTSP LEL or rWbTSP LEL for 1hr at room temperature (RT). After washing with PBST, membranes were incubated for 1hr at room temperature with a secondary goat anti-mouse IgG antibodies conjugated to HRP (1:5000, Thermo Fisher). Color was developed using diamino benzidine (Thermo Fisher Scientific) substrate.

Analysis of vaccine induced protection in mice

Two weeks after the final vaccination we performed the in vivo challenge experiments by surgically implanting 20 B. malayi L3 in a micropore chamber in the peritoneal cavity of each mouse [36,37]. After 48 hours, mice were sacrificed and the chambers were surgically removed and examined under the microscope to determine the larval viability. Percent larval death was determined as described before [36,37].

Antigen specific proliferation assay

Antigen specific proliferation of mouse spleen cells were evaluated as described previously [34]. Briefly, 1 x 10^5 splenocytes were stimulated with (a) 1 μg/ml of rWbTSP LEL or 1 μg/ml of rBmTSP LEL, (b) 1 μg/ml of a non-specific recombinant protein (recombinant S. mansoni G-binding factor, rSmGBF), (c) 1 μg/ml of ConA or (d) medium alone (unstimulated) in triplicate wells for 72hrs at 37°C. Stimulation index (S.I) was calculated from the unstimulated controls. For cytokine analysis, splenocytes were stimulated with 1 μg/ml of rWbTSP LEL and medium alone (unstimulated) for 72 hrs.

Antigen specific proliferation of PBMC was also determined similarly as described previously [34]. Briefly, PBMC were isolated from heparinized venous blood of study subjects using histopaque 1077 column (Sigma). Isolated PBMC were stimulated with (a) 1 μg/ml of rWbTSP LEL, (b) 1 μg/ml of ConA (positive control), or (c) medium alone (unstimulated controls). PBMC were stimulated in triplicate wells at 37°C in 5% CO2 for 72h. Cell proliferation was measured using an MTT assay (Cell Titer 96 R aqueous non-radioactive cell proliferation assay, Promega, Madison, WI). Stimulation indices (S.I) were calculated as above. For cytokine analysis, PBMC were stimulated with 1 μg/ml of rWbTSP LEL and medium alone (unstimulated) for 72 hrs.

Analysis of cytokine levels in the culture supernatants of the antigen specific cells

After 72hrs of stimulation with the antigens, culture supernatants of splenocytes were collected and the levels of secreted cytokines (IL-1, IL-4, IL-5, IL-10, IFN-γ, TNF-α) were measured using multianalyte ELISA array kit according to manufacturer’s instructions (SA biosciences, Valencia, CA). Cytokine values in the culture supernatant of cells incubated with rSmGBF or media alone was used as the background value. For human assays, levels of Interferon-γ (IFN-γ), Interleukin-4 (IL-4) and Interleukin-10 (IL-10) were estimated in the culture supernatants of PBMC 72 hrs after incubation using human cytokine ELISA kits (E-biosciences, San Diego, CA) as per the manufacturer’s instruction. Sensitivity and minimum detection limits of the kits were 0.05 - 0.1 pg/ml. Concentration of each cytokine in the culture supernatant was plotted from a
Both LF human and mice sera carry cytophillic antibodies against TSP LEL

Expression of TSP LEL on the surface of B. malayi makes the antigen easily available to the host immune system. To determine if the sera from putatively immune and infected individuals carry antibodies against filarial TSP LEL, we first screened for the presence of anti-TSP LEL antibodies in the sera of different subjects (EN, CP, MF and NEN) using an indirect ELISA. Our results show that 14 out of 15 putatively immune endemic normal (EN) individuals carry circulating IgG antibodies against rWbTSP LEL (Figure 2) proteins. No significant levels of IgG were observed in the sera samples of MF, CP and NEN individuals. Positive reactions in the EN sera were determined as readings above the cut off value of mean + 3SD of NEN OD values. We also analyzed the isotype of anti-WbTSP LEL IgG antibodies in these sera samples. Our results showed that anti-TSP LEL IgG1 were predominant in the sera of EN individuals (Figure 3) compared to sera from other filarial groups (MF and CP). High levels of IgG3 antibodies were found both in EN and CP individuals. IgG2 and IgG4 isotypes did not show any significant differences between the filarial groups. Anti-TSP LEL IgG antibodies were not detectable in the sera of NEN individuals. Similar antibody responses were observed against rBmTSP LEL (data not shown).

Anti-TSP LEL antibodies participated in the killing of B. malayi L3 in an ADCC mechanism

Results presented above show that sera of EN subjects and immunized mice have significantly high titer of anti-TSP LEL IgG antibodies. IgG antibodies can bind to FcyRI and FcyRII receptors expressed on several inflammatory cells such as macrophages, neutrophils, eosinophils and participate in an ADCC mechanism [40]. Therefore, in this study we evaluated if anti-TSP LEL antibodies in the sera of EN subjects and immunized mice can participate in the killing of B. malayi L3 in vitro in an ADCC assay. Our results show that pooled sera samples from EN subjects were able to kill 65% of B. malayi L3 in an ADCC assay. Depletion of anti-WbTSP-LEL antibodies from the sera of EN subjects resulted in the reduction of the killing ability of the sera by 2/3. When we depleted total IgG from the sera of EN subjects the killing ability was reduced by 85%. Incubating the larvae with cells alone or sera alone killed only <5% of L3 (Figure 5A). A similar ADCC assay performed using sera samples from immunized mice showed that ~67% of B. malayi L3 were killed when immune sera was used, whereas, only 5% of L3 were killed when sera samples from control animals were used (Figure 5B). These findings suggest that the anti-TSP LEL antibodies play a critical role in the killing of B. malayi L3 in vitro.

Antibodies in the sera of EN subjects can recognize rOvTSP LEL.

Another important finding in this study was that the IgG antibodies in the sera of EN subjects could recognize rOvTSP LEL. Further analysis showed that the rOvTSP LEL recognizing
antibodies in the sera of EN subjects were of IgG1 and IgG3 isotype. This suggested that potentially the same antibodies may be recognizing both rWbTSP LEL and rOvTSP LEL. This was not surprising given the significant sequence similarities between OvTSP LEL and WbTSP LEL.

We then tested the reverse cross reactivity, that is, if antibodies in the sera of Ov-PI subjects (these are PI subjects from an O. volvulus endemic area in Cameroon) will react with rWbTSP LEL. Our results show that IgG1 specific antibodies in the sera of Ov-PI individuals recognized rWbTSP LEL proteins (Figure 6A). Levels of anti-WbTSP LEL IgG3 antibodies were not significantly different in the sera of Ov-PI subjects and O. volvulus infected patients (Figure 6B). These findings suggested the presence of cross reactive IgG1 antibodies in the sera of LF-EN and Ov-PI subjects.

Vaccination of mice with rTSP LEL conferred protection against a challenge infection.

Vaccine potential of rBmTSP LEL or rWbTSP LEL was confirmed in the mouse model by challenging with 20 B. malayi L3 in a micropore chamber. Mice vaccinated with rBmTSP LEL and/or rWbTSP LEL gave 65% and 67% protection respectively against B. malayi L3 challenge (Table 1).

rTSP LEL specific IFN-γ secreting cells were present in the PBMC of EN subjects and in vaccinated mice. PBMC from putatively immune EN subjects and spleen cells from vaccinated mice proliferated significantly in response to rWbTSP LEL stimulation suggesting the presence of antigen-specific memory cell population in both human and mice (Figure 7A and 7B). The stimulation indices were 1 fold and 2 folds higher compared to NEN individuals and control mice respectively. PBMC from MF and CP individuals did not show
any significant proliferations. Similarly, spleen cells from control mice also did not show any significant proliferation.

Analysis of the levels of secreted cytokines in the culture supernatants of PBMC stimulated with rWbTSP LEL showed that significantly high levels of IFN-γ (168 pg/ml) (P<0.001) was secreted by PBMC from EN subjects, whereas, PBMC from MF individuals secreted predominantly IL-10 (210 pg/ml) (Figure 8A). There were no significant differences in the levels of IL-4 in the culture supernatants of PBMC from different groups.

Figure 2. TSP LEL specific IgG antibodies in the sera of LF human subjects. Levels of total IgG antibodies against rWbTSP LEL in the sera of Endemic normal (EN), Microfilaremic (MF), Chronic pathology (CP) and Non-endemic normal (NEN) subjects were measured using an indirect ELISA. 15 sera samples (diluted 1:100) were evaluated from EN, and 10 samples from MF, CP and NEN individuals. Each data point represents sera sample from a single individual. Horizontal lines represent geometric mean value. Data is represented as scatter plot where each dot represents absorbance of individual sera. Significant (*P<0.05) IgG antibodies in EN individuals compared to other groups (One way ANOVA along with Tukey-Kramer post statistics test was used).

doi: 10.1371/journal.pone.0077394.g002

Figure 3. TSP LEL specific IgG isotype of antibodies in the sera of human. Isotype of IgG antibodies A) IgG1, B) IgG2, C) IgG3 and D) IgG4 against rWbTSP LEL were measured in the sera of putatively immune individuals (n=10) using an indirect ELISA. Each data point represents sera sample from a single individual. Horizontal lines represent geometric mean value. Data is represented as scatter plot where each dot represents absorbance of individual sera. Significant (*P<0.05) levels of isotype antibodies in EN individuals compared to other groups (One way ANOVA along with Tukey-Kramer post statistics test was used).

doi: 10.1371/journal.pone.0077394.g003

Figure 4. TSP LEL specific IgG antibodies in the sera of mice. Mice were immunized four times at two weeks interval using 15 µg of rWbTSP LEL combined with alum adjuvant. A) Titer of anti-TSP LEL IgG antibodies. Approximately, 100 ng of recombinant proteins (100 ng /100µl /well) were coated onto the wells of an ELISA plate and bound serum IgG was detected using an HRP-labeled anti-mouse IgG secondary antibody. Each data point indicates mean ±S.D value from five animals. B). Isotype of anti-TSP LEL IgG antibodies in the sera of mice. Isotypes specific ELISA was performed as described in the methods section. Bars represent mean ±SD from five mice per group. ** Significant (P<0.001) and * (P<0.05) compared to control groups (Student’s t-test).

doi: 10.1371/journal.pone.0077394.g004
Splenocytes from mice immunized with rWbTSP LEL secreted significant (P<0.05) amounts of IFN-γ (550 pg/ml) and IL-10 (300 pg/ml) in response to rWbTSP LEL (Figure 8B). However, secreted levels of IL-1, TNF-α, IL-4 and IL-5 were not significantly different in the culture supernatants of splenocytes compared to control.

Discussion

Lymphatic filariasis is the second leading cause of disability in the world [41], and is thus considered a major obstacle to economic development in the developing countries where this disease is endemic. Mass drug administration sphere headed by the World Health Organization is making substantial headway in reducing the incidence of this infection in several parts of the world [4]. Additional strategies such as vector control measures and an effective vaccine to prevent lymphatic filariasis will substantially supplement the effort towards elimination of this disease. Several previous studies have shown the feasibility of developing a vaccine against lymphatic filariasis and a number of potential antigens were identified as suitable candidates for vaccine against this infection in experimental animals [5, 7-9, 42]. In this study we show that TSP LEL is present in several filarial parasites.

Table 1. Vaccine induced protection in mice.

| Animal groups | S.D | Mean ± S.D | Mean ± S.D |
|---------------|-----|------------|------------|
| **Trial-I**   |     |            |            |
| Alum (Control)| 16±1.34 | 1.4±0.543   | 8.27±2.592 |
| rWbTSP LEL    | 18±2.70 | 11.6±2.073  | 63.2±7.505** |
| rBmTSP LEL    | 16±2.70 | 10.6±0.894  | 65.4±6.898** |
| **Trial-II**  |     |            |            |
| Alum (Control)| 19.2±2.38 | 2.2±0.83    | 2.2±0.83   |
| rWbTSP LEL    | 15±0.707 | 9.75±1.14   | 64.2±9.49** |
| rBmTSP LEL    | 17.2±2.79 | 10.25±1.67  | 60.3±3.46** |

In vivo micropore chamber assay was performed by surgically implanting 20 B. malayi L3 into the peritoneal cavity of each mouse. 48 hrs after implantation, chambers were removed and larval viability and larval death was determined. Values are mean ± SD. N = 5. Data presented here is from one of two similar experiments showing comparable results. **. significant larval death (P<0.001) compared to control mice groups analyzed by one way ANOVA followed by Dunnett’s post ANOVA test.

doi: 10.1371/journal.pone.0077394.t001

doi: 10.1371/journal.pone.0077394.g006

doi: 10.1371/journal.pone.0077394.g005

doi: 10.1371/journal.pone.0077394.g007

Figure 5. Sera from EN subjects and mice immunized with rWbTSP LEL participated in the killing of B. malayi L3 in an ADCC mechanism. A) 50 µl of pooled EN sera (n = 10) samples or sera samples depleted off anti-TSP LEL antibodies were incubated with 2x10⁵ peripheral blood mononuclear cells from normal healthy individuals and 10 B. malayi L3 for 48 hrs at 37°C. B) 50 µl of pooled sera (n = 5) samples from rWbTSP LEL immunized or rBmTSP LEL immunized mice were incubated with 2x10⁵ peritoneal exudates cells from naive mice and 10 B. malayi L3 for 48 hrs at 37°C. Larval viability was evaluated at the end of the incubation. Values represent mean ± SD of three wells. Significant larval death ** (P<0.001) compared to controls analyzed by Student’s t-test.

Figure 6. Sera from individuals who are putatively immune against O. volvulus infections (PI) has antibodies that cross react with rWbTSP LEL. Isotype of IgG antibody A) IgG1 and B) IgG3 reactivity was measured in the sera of putatively immune individuals (PI) and O. volvulus infected individuals (INF) against rWbTSP LEL. Each data point represents sera sample from a single individual (n=20). Horizontal lines represent median value. Data is represented as scatter plot where each dot represents absorbance of individual sera. PI sera showing significant (P<0.001) cross reactivity of IgG1 antibodies compared to INF individuals. The OD of NEN (NYC individuals) was always below OD 0.1. Significant (P<0.001) levels of isotype antibodies in PI compared to INF group (Student’s t-test).

Spleenocytes from mice immunized with rWbTSP LEL secreted significant (P<0.05) amounts of IFN-γ (550 pg/ml) and IL-10 (300 pg/ml) in response to rWbTSP LEL (Figure 8B). However, secreted levels of IL-1, TNF-α, IL-4 and IL-5 were not significantly different in the culture supernatants of splenocytes compared to control.
is present in *B. malayi* L3, adults and Mf stages [21]. Thus, all stages of the parasite may potentially express TSP LEL suggesting an important role for this protein in these parasites. Targeting TSP by developing a vaccine against TSP LEL afforded substantial protection against primary alveolar echinococcosis [46] and *S. mansoni* [12]. These reports suggested that TSP LEL is an attractive target for developing a vaccine against helminthes.

Our previous studies showed that differential recognition of protective filarial antigens by endemic normal individuals can be a useful and rigorous approach to identify vaccine candidates against filarial infections [47]. Several previous studies demonstrate the presence of high titer of antibodies against key antigens in the sera of putatively immune endemic normal individuals [48,49]. In vitro ADCC assays confirm that these antibodies can participate in the killing of infective larvae.
of filarial parasites. Presence of these host protective antibodies in EN subjects, but not in the infected individuals (MF, CP) potentially suggests a strong correlation for selecting the candidate antigen that elicited the protective antibodies for further testing as a vaccine candidate. Based on this paradigm, in this study we first analyzed if anti-TSP LEL antibodies are uniquely present in EN subjects. Our results confirm the presence of high titer of anti-TSP LEL IgG antibodies in the putative immune EN subjects. These anti-TSP LEL IgG antibodies were found to be primarily cytophilic antibodies (IgG1 and IgG3). Similar antibody responses (IgG1 and IgG3) were demonstrated against SmTSP-2 LEL as well in individuals who are putatively resistant against schistosomiasis [12]. These findings suggest that parasite TSP LEL in general induces similar antibody responses in human. No detectable levels of rWbTSP LEL specific IgE antibodies were present in the sera of EN or in the sera of subjects who have filarial infection (MF and CP) (data not shown). This suggests that if rWbTSP LEL were to be developed as a vaccine for human use, potential allergic reactions will be minimal.

Immunization of mice with rBmTSP LEL or rWbTSP LEL resulted in the generation of anti-TSP LEL IgG1, IgG2a and IgG2b antibodies similar to that reported in mice vaccinated with Sm-TSP-2 [12]. These findings also suggested that parasite TSP LELs potentially induces similar types of antibody responses in the mouse model. Immune human subjects carry anti-TSP LEL IgG1 and IgG3 antibodies which is equivalent to IgG2a and IgG2b in mouse.

IgG1 and IgG3 antibodies can mediate antibody-dependent cellular cytotoxicity (ADCC) [50] and phagocytosis [51] by a variety of effector cells that express FcyRI and FcyRII. Elevated levels of these cytophilic antibodies against rWbTSP LEL in putatively immune EN subjects and immunized mice suggested that these antibodies may participate in the killing of the parasite via ADCC mechanism. In fact, our results confirm that the anti-WbTSP LEL antibodies in LF-EN subjects and immunized mice have the ability to participate in the killing of B. malayi L3 through an ADCC mechanism. When we depleted the anti-WbTSP LEL antibodies from the sera samples, ability of the sera samples to participate in the killing B. malayi L3 was substantially decreased suggesting a key role for the anti-WbTSP LEL antibodies in the killing mechanism. These findings suggested that the anti-WbTSP LEL antibodies may have an important role in the defense against this parasitic infection in human.

Subsequently we evaluated the vaccine potential of rWbTSP LEL in the mouse model using a micropore chamber challenge approach. Although this is not a true challenge model, given the difficulty in performing immunological analysis in jirds and due to prohibitive cost for the primate trials, the mouse micropore challenge system was used as a surrogate to challenge studies. Nevertheless, the data was interpreted with caution. Our results showed that immunization with rBmTSP LEL or rWbTSP LEL conferred 65% larval killing in this model. Compared to other vaccine proteins (BmHSP12.6, BmGST, BmVAL, BmTFX-2) tested in our laboratory [25][33] [35][42], rBmTSP LEL or rWbTSP LEL appears to be a good vaccine candidate against B. malayi. We also observed several cells attached firmly to the dead larvae in the micropore chambers. We did not identify the morphology of these cells; however, based on our ADCC results, we believe that these are possibly the effector cells. Protection conferred by rBmTSP LEL or rWbTSPPLEL is also comparable to the protection reported for SmTSP-2 (57%–64%) in mice [12]. Similarly, vaccination trials in cestode infections also suggest that TSP is an attractive vaccine candidate against helminthes [46].

Evaluation of the immune correlates of rBmTSP LEL-induced protection showed that antigen specific memory cells are present in putatively immune LF-EN subjects and in vaccinated mice. Analysis of the cytokines secreted by these antigen-specific proliferating cells revealed that both PBMC from immune individuals and vaccinated mice splenocytes secreted IFN-γ and IL-10 in response to rTSP LEL stimulation. These findings were similar to those reported after vaccination of mice with SmTSP-2 [52]. Presence of antigen-specific IFN-γ secreting cells together with IL-10 secreting cells in the spleen suggest a balanced Th1/Th2 immune responses that may be important for regulating the inflammation caused by the host-protective mechanism in the filarial infections or for preventing the development of highly polarized Th1 responses [53,54]. Increase in the levels of IFN-γ suggests the activation of macrophages that may be important in the ADCC mediated killing of parasites observed in our studies [35] and others [55].

Another important observation in our studies is the finding that the TSP LEL sequences from different filarial parasites (B. malayi, W. bancrofti, O. volvulus) share sequence identity. This was reflected in the anti-TSP LEL antibody cross reactivity observed in the sera of putatively immune individuals for lymphatic filariasis and onchocerciasis. Because of the significance sequence identity, filarial TSP LEL can be used as a cross-protective vaccine antigen against both lymphatic filariasis and possibly O. volvulus infections in human. This observation has broader implications for the control of both the infections, especially, in parts of Africa where both these infections occur as co-infections [4]. However, challenge studies in animals are required to confirm this. Recently there is significant interest in identifying cross-protective vaccine antigens that are effective against multiple closely-related pathogens in an effort to reduce the cost of manufacturing and development pipelines [56].

In summary, we show that TSP LEL is expressed on the surface of B. malayi L3 and are thus easily accessible to the host immune system. The fact that putatively immune individuals carry IgG1 and IgG3 antibodies against WbTSP LEL and these antibodies participate in the killing of L3 in an ADCC assay confirm the potential of this antigen as a vaccine candidate against lymphatic filariasis. Our vaccination trials in the mouse model confirm this notion. Significant cross-reactivity of the anti-WbTSP LEL IgG1 antibodies in the sera of individuals who are protected against both lymphatic filarial and onchocerciasis infections suggest that WbTSP LEL could be developed as a potential vaccine candidate against onchocerciasis. These are only preliminary observations additional trials are needed to confirm the vaccine potential of rTSP LEL against filarial infections.
Acknowledgements

We would like to thank John Javeherian for the technical assistance with the animal experiments. *B. malayi* third stage infective larvae (L3) were obtained from NIH/NIH/NIH filariasis research reagent resource center, College of Veterinary Medicine, University of Georgia, Athens, GA. We also thank Dr. Sara Lustgaman and Nancy Tricoche of the Lindsey F. Kimball Research Institute, New York Blood Center, NY, for performing the ELISA with the repository sera from Cameroon, which was collected from participating individuals living in the villages around Kumba (Marumba I, Marumba II, Boa Bakundu, Bombanda, and Bombele).

Author Contributions

Conceived and designed the experiments: GD KS GM RK. Performed the experiments: GD KS GM RK. Analyzed the data: GD MR RK. Contributed reagents/materials/analysis tools: GD MR RK. Wrote the manuscript: GD KS RK.

References

1. Michael E, Nutman TB (2000) Lymphatic filariasis. Tropical Medicine: Science and Practice London: Imperial College Press vol. 1: 41-82.
2. Lahariya C, Tomar SS (2011) How endemic countries can accelerate health interventions to eliminate lymphatic filariasis. PLoS Med 8: e1000936. PubMed: 21406730.
3. Patel V, Ramasundaraththegi C, Vijayakumar L, Thakur JS, Gajalakshmi V, et al. (2012) Suicide mortality in India: A nationally-representative survey. Lancet 379: 2343-2351. doi:10.1016/S0140-6736(12)60606-0. PubMed: 22726517.
4. Hotez PJ (2009) Mass drug administration and integrated control for the world’s neglected neglected tropical diseases. Clin Pharmacol Ther 85: 659-664. doi:10.1038/cpt.2009.16. PubMed: 19322166. Retrieved on published at whilst December year 2011 from .
5. Mathurmani J, Prince PR, Anugraha K, Kiran P, Rao DN et al. (2010) Identification and characterization of nematode specific protective epitopes of *Brugia malayi* TRX towards development of synthetic vaccine construct for lymphatic filariasis. Vaccine 28: 5038-5048. doi: 10.1016/j.vaccine.2010.05.012. PubMed: 20565106.
6. Murray J, Gregory WF, Gomez-Escobar N, Atmadja AK, Maizels RM (2003) Hematopermeability of filarial worms in the mammalian microcirculation. J Infect Dis 188: 1207-1216. doi:10.1086/376337. PubMed: 12971387.
7. Pokharel DR, Rai R, Nandakumar K, Reddy MV, Rathnur S (2006) Vaccination with *Setaria cervi* 175 KDa collagenase induces high level of protection against *Brugia malayi* infection in jirds. Vaccine 24: 6208-6215. doi:10.1016/j.vaccine.2006.05.012. PubMed: 16870314.
8. Sahoo MK, Sisodia BS, Dixit S, Joseph SK, Gaur RL et al. (2009) Immunization with inflammatory proteome of *Brugia malayi* adult worm induces a Th1/Th2-immune response and confers protection against the filarial challenge. Vaccine 27: 4263-4271. doi:10.1016/j.vaccine.2009.05.015. PubMed: 19450648.
9. Vedi S, Dangi A, Hajela K, Misra-Bhattacharya S (2008) Vaccination with 73kDa recombinant heavy chain myosin generates high level of protection against *Brugia malayi* challenge in jird and Mastomys models. Vaccine 26: 5997-6005. doi:10.1016/j.vaccine.2008.07.073. PubMed: 18817835.
10. Schmid-Hempel P (2009) Immune defence, parasite evasion strategies and their relevance for macroscopic phenomena such as virulence. Philos Trans R Soc Lond B Biol Sci 364: 85-98. doi:10.1098/rstb.2008.0157. PubMed: 18930879; Retrieved on published at whilst December year 2011 from .
11. Natterer HT, Todd SC, Levy S (1997) The tetraspanin superfamily: Molecular facilitators. FASEB J 11: 422-448. PubMed: 9194523.
12. Tran MH, Pearson MS, Allen JG, Nayak SB, et al. (2010) Future prospects and challenges of vaccines against filariasis. Parasite Immunol 34: 243-253. doi:10.1111/j.1365-3204.2011.01350.x. PubMed: 21250082; Retrieved on published at whilst December year 2011 from .
13. Taylor MJ, Hoerauf A, Bockarie M (2010) Lymphatic filariasis and onchocerciasis. Lancet 376: 1175-1185. doi:10.1016/S0140-6736(10)60586-7. PubMed: 20739055; Retrieved on published at whilst December year 2011 from .
14. Cassone A, Rappuoli R (2010) Universal vaccines: Shifting to one for many. mBio 1: (MedlinePgn: doi:10.1128/mBio.00042-10. PubMed: 20669748. Retrieved on published at whilst December year 2011 from .
15. Anand SB, Rajagopal V, Kaliraj P (2012) *Brugia malayi* thioredoxin peroxidase as a potential vaccine candidate antigen for lymphatic filariasis. Appl Biochem Biotechnol 167: 1351-1364. doi:10.1007/s12010-012-9643-6. PubMed: 22528646; Retrieved on published at whilst December year 2011 from .
16. Makepeae BL, Jensen SA, Laney SJ, Nfon CK, Njongmeta LM et al. (2009) Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure. PLoS Neg Trop. Dis. Drosophila Inf Serv 3: e544. doi: 10.1371/journal.pntd.0000544; Retrieved on published whilst December year 2011 from . doi:10.1371/journal.pntd.0000544.
17. Wang J, Tricoche N, Du L, Hunter M, Zhan B et al. (2012) The advantucity of an O. volvulus-derived Ov-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLOS ONE 7: e307019. doi:10.1371/journal.pone.00307019. PubMed: 22615877; Retrieved on published whilst December year 2011 from . doi:10.1371/journal.pone.00307019.
18. Steel C, Guinea A, Ottesen EA (1996) Evidence for protective immunity to bancroftian filariasis in the cock islands. J Infect Dis 174: 596-605. doi:10.1093/infdis/174.3.586. PubMed: 8769619.
29. Rao KV, Eswaran M, Ravi V, Gnanasekhar B, Narayanan RB et al. (2000) The Brugia malayi savvy proteome: cloning and expression of infective larval stage specific genes. Mol Biochem. Parasitol 107: 71-80. doi:10.1016/S0166-6851(00)00231-5. PubMed: 10717303.

30. Cho-Ngwa F, Liu J, Lustigman S (2010) The Onchocerca volvulus cysteine proteinase inhibitors, ov-CP1-2, is a target of protective antibody response that increases with age. PLoS Negl Trop. Drosophila inf Serv 4: e800. doi:10.1371/journal.pntd.0000800; Retrieved unpublished at whilst December year 1111 from . doi:10.1371/journal.pntd.0000800

31. MacDonald AJ, Turaga PS, Harmon-Brown C, Tierney TJ, Bennett KE et al. (2002) Differential cytokine and antibody responses to adult and larval stages of Onchocerca volvulus consistent with the development of concomitant immunity. Infect Immun 70: 2796-2804. doi:10.1128/IAI.70.11.2796-2804.2002. PubMed: 12152622.

32. Kurniawan-Atmadja A, Sartono E, Partono F, Yazdanbakhsh M, Maiels RM (1998) Antibody responses to filarial infective larvae are not dominated by the IgG4 isotype. Parasite Immunol 20: 9-17. doi:10.1046/j.1469-0691.2000.00735.x; Retrieved on published at whilst December year 1111 from . doi:10.1371/journal.pntd.0001366

33. Veerapathran A, Dakshinamoorthy G, Gnanasekar M, Reddy MV, Kalyanasundaram R (2009) Evaluation of Wuchereria bancrofti GST as a vaccine candidate for lymphatic filariasis. PLoS Negl Trop. Drosophila inf Serv 3: e457. doi:10.1371/journal.pntd.0000457.

34. Dakshinamoorthy G, Samykutty AK, Munirathinam G, Shinde GB, Nutman T et al. (2012) Biochemical characterization and evaluation of a Brugia malayi small heat shock protein as a vaccine against lymphatic filariasis. PLOS ONE 7: e34077. doi:10.1371/journal.pone.0034077. PubMed: 22498777.

35. Dakshinamoorthy G, Samykutty AK, Munirathinam G, Reddy MV, Kalyanasundaram R (2013) Multivalent fusion protein vaccine for lymphatic filariasis. Vaccine31: 1616-1622. doi:10.1016/j.vaccine.2012.09.055; Retrieved unpublished at whilst December year 1111 from . doi:10.1371/journal.pntd.2012.09.055

36. Abraham D, Grieve RB, Holy JM, Christensen BM (1989) Immunity to larval development. Am J Trop Med Hyg 40: 598-604. PubMed: 2662785.

37. Samykutty AK, Dakshinamoorthy G, Kalyanasundaram R (2010) Multivalent vaccine for lymphatic filariasis. Procedia Vaccinol 3: 12-18. doi:10.1016/j.provac.2010.11.003. PubMed: 21078865.

38. Levy S, Shoaham T (2005) The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 5: 136-148. doi:10.1038/nr1548. PubMed: 15888041.

39. Cupt PM, Steinauer ML, Tonnessen BW, Eric Agola L, Kinuthia JM et al. (2011) Polymorphism associated with the orthologue of SXP1 and GST as an antigen by infection-free individuals in an endemic area. J Clin Invest 83: 14-22. doi:10.1172/JCI83407.

40. Pearson MS, Pickering DA, McSorley JH, Bethony JM, Mbodo L et al. (2012) Enhanced protective efficacy of a chimeric form of the filarial protein follicular chemotactic factor. J Exp Med 209: 1103-1107. doi:10.1083/jcb.200108061. PubMed: 11756464.

41. Kipps TJ, Parham P, Junt J, Herzenberg LA (1985) Importance of immunoglobulin isotype in human antibody-dependent, cell-mediated cytotoxicity directed by murine monoclonal antibodies. J Exp Med 161: 981-988. doi:10.1084/jem.161.1.1. PubMed: 3918141.

42. Freedman DO, Nutman TB, Ottesen EA (1999) Protective immunity in human lymphatic filariasis: Problems and prospects. Med Microbiol Immunol 192: 41-46. doi:10.1007/s00430-002-0157-7. PubMed: 12592562.

43. Stewart GR, Zhu Y, Parwares W, Tree TJ, Guderian R et al. (1997) The novel cuticular collagen ov-col-1 of Onchocerca volvulus is preferentially recognized by immunoglobulin G3 from putatively immune individuals. Infect Immun 65: 164-170. PubMed: 8975907.

44. Dang Z, Yagi K, Oku Y, Kouguchi H, Kajino K et al. (2012) A pilot study on developing moscal vaccine against alveolar echinococcosis (AE) using recombinant tetraspanin 3: Vaccine efficacy and immunology. PLoS Negl Trop. Drosophila Inf Serv 6: e1570. doi:10.1371/journal.pntd.0001570; Retrieved unpublished at whilst December year 1111 from . doi:10.1371/journal.pntd.0001570

45. Helmer ME (2001) Specific tetraspanin functions. J Cell Biol 155: 1103-1107. doi:10.1083/jcb.200108061. PubMed: 11756464.

46. Dang Z, Yagi K, Oku Y, Kouguchi H, Kajino K et al. (2009) Evaluation of Echinococcus multilocularis tetraspanins as vaccine candidates against primary alveolar echinococcosis. Vaccine 27: 7339-7345. doi:10.1016/j.vaccine.2009.09.045. PubMed: 19738212; Retrieved unpublished at whilst December year 1111 from . doi:10.1016/j.vaccine.2009.09.045

47. Fan S, Fehr HG, Adams D (1991) Activation of macrophages for ADCC functions. Immunology 66: 491-498. PubMed: 2523858.

48. Rozsnay Z, Sármay G, Walker M, Maslanka K, Valasek Z et al. (1989) Distinctive role of IgG1 and IgG3 isotypes in Fc receptor-mediated killing of Drosophila melanogaster cells. Immunol Lett 26: 41-46. doi:10.1016/0165-2478(89)90080-3. PubMed: 23065953.

49. Lee KS, Leberberg J, McDonald K, Leggatt GR, Frazer IH (2009) IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host. J Immunol 183: 51-58. doi:10.4049/jimmunol.0802047. PubMed: 19535638; Retrieved unpublished at whilst December year 1111 from . doi:10.1371/journal.pntd.0001564

50. Liu XS, Fan S, Fehr HG, Adams D (1991) Activation of macrophages for ADCC in vitro: Effects of IL-4, TNF, interferons-α/β, interferon-γ, and GM-CSF. Cell Immunol 135: 78-87. doi:10.1016/0046-9247(91)90025-A. PubMed: 1708310.

51. Hoerauf A, Pfarr K, Mand S, Debrah AY, Specht S (2011) Filariasis in Africa–treatment challenges and prospects. Clin Microbiol Infect 17: 977-985. doi:10.1111/j.1469-0691.2011.03586.x. PubMed: 21722251; Retrieved unpublished at whilst December year 1111 from . doi:10.1111/j.1469-0691.2011.03586.x